254 related articles for article (PubMed ID: 23985681)
61. APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma.
Faden DL; Ding F; Lin Y; Zhai S; Kuo F; Chan TA; Morris LG; Ferris RL
Oral Oncol; 2019 Sep; 96():140-147. PubMed ID: 31422205
[TBL] [Abstract][Full Text] [Related]
62. Association of recurrent APOBEC3B alterations with the prognosis of gastric-type cervical adenocarcinoma.
Liao X; Xia X; Su W; Yan H; Ma Y; Xu L; Luo H; Liu W; Yin D; Zhang WH; Chen HN; Deng Y; Ren Z; Yu Z; Liao F; Chen K; Cao M; Zhang Y; Zhang W; Wang W; Zhao JN; Xu H; Shu Y
Gynecol Oncol; 2022 Apr; 165(1):105-113. PubMed ID: 35151492
[TBL] [Abstract][Full Text] [Related]
63. Analysis of APOBEC3A/3B germline deletion polymorphism in breast, cervical and oral cancers from South India and its impact on miRNA regulation.
Revathidevi S; Manikandan M; Rao AK; Vinothkumar V; Arunkumar G; Rajkumar KS; Ramani R; Rajaraman R; Ajay C; Munirajan AK
Tumour Biol; 2016 Sep; 37(9):11983-11990. PubMed ID: 27155849
[TBL] [Abstract][Full Text] [Related]
64. Genetics: APOBEC-a double-edged sword.
Razzak M
Nat Rev Clin Oncol; 2013 Sep; 10(9):488. PubMed ID: 23897082
[No Abstract] [Full Text] [Related]
65. The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer.
Liu J; Sieuwerts AM; Look MP; van der Vlugt-Daane M; Meijer-van Gelder ME; Foekens JA; Hollestelle A; Martens JW
PLoS One; 2016; 11(8):e0161731. PubMed ID: 27552096
[TBL] [Abstract][Full Text] [Related]
66. PrimPol prevents APOBEC/AID family mediated DNA mutagenesis.
Pilzecker B; Buoninfante OA; Pritchard C; Blomberg OS; Huijbers IJ; van den Berk PC; Jacobs H
Nucleic Acids Res; 2016 Jun; 44(10):4734-44. PubMed ID: 26926109
[TBL] [Abstract][Full Text] [Related]
67. APOBEC3B deletion and risk of HIV-1 acquisition.
An P; Johnson R; Phair J; Kirk GD; Yu XF; Donfield S; Buchbinder S; Goedert JJ; Winkler CA
J Infect Dis; 2009 Oct; 200(7):1054-8. PubMed ID: 19698078
[TBL] [Abstract][Full Text] [Related]
68. A systems biology analysis of protein-protein interactions in the APOBEC family.
Wang Y; Chen G; Yang Y; Hu Z; Chen X
Life Sci; 2008 Oct; 83(15-16):521-30. PubMed ID: 18793652
[TBL] [Abstract][Full Text] [Related]
69. APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition.
Buisson R; Lawrence MS; Benes CH; Zou L
Cancer Res; 2017 Sep; 77(17):4567-4578. PubMed ID: 28698210
[TBL] [Abstract][Full Text] [Related]
70. APOBEC and ADAR deaminases may cause many single nucleotide polymorphisms curated in the OMIM database.
Lindley RA; Hall NE
Mutat Res; 2018 Jul; 810():33-38. PubMed ID: 29957488
[TBL] [Abstract][Full Text] [Related]
71. Genomic Characterization Revealed PM
Fan R; Xu L; Cui B; Li D; Sun X; Qi Y; Rao J; Wang K; Wang C; Zhao K; Zhao Y; Dai J; Chen W; Shen H; Liu Y; Yu D
Environ Sci Technol; 2023 May; 57(17):6854-6864. PubMed ID: 37071573
[TBL] [Abstract][Full Text] [Related]
72. An extended APOBEC3A mutation signature in cancer.
Langenbucher A; Bowen D; Sakhtemani R; Bournique E; Wise JF; Zou L; Bhagwat AS; Buisson R; Lawrence MS
Nat Commun; 2021 Mar; 12(1):1602. PubMed ID: 33707442
[TBL] [Abstract][Full Text] [Related]
73. RNA-editing cytidine deaminase Apobec-1 is unable to induce somatic hypermutation in mammalian cells.
Eto T; Kinoshita K; Yoshikawa K; Muramatsu M; Honjo T
Proc Natl Acad Sci U S A; 2003 Oct; 100(22):12895-8. PubMed ID: 14559972
[TBL] [Abstract][Full Text] [Related]
74. APOBEC3B High Expression in Gastroenteropancreatic Neuroendocrine Neoplasms and Association With Lymph Metastasis.
Feng C; Zheng Q; Yang Y; Xu M; Lian Y; Huang J; Jiang Y
Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):599-605. PubMed ID: 30095460
[TBL] [Abstract][Full Text] [Related]
75. APOBEC Mutagenesis and Copy-Number Alterations Are Drivers of Proteogenomic Tumor Evolution and Heterogeneity in Metastatic Thoracic Tumors.
Roper N; Gao S; Maity TK; Banday AR; Zhang X; Venugopalan A; Cultraro CM; Patidar R; Sindiri S; Brown AL; Goncearenco A; Panchenko AR; Biswas R; Thomas A; Rajan A; Carter CA; Kleiner DE; Hewitt SM; Khan J; Prokunina-Olsson L; Guha U
Cell Rep; 2019 Mar; 26(10):2651-2666.e6. PubMed ID: 30840888
[TBL] [Abstract][Full Text] [Related]
76. AID/APOBEC-like cytidine deaminases are ancient innate immune mediators in invertebrates.
Liu MC; Liao WY; Buckley KM; Yang SY; Rast JP; Fugmann SD
Nat Commun; 2018 May; 9(1):1948. PubMed ID: 29769532
[TBL] [Abstract][Full Text] [Related]
77. Hepatitis B: modern concepts in pathogenesis--APOBEC3 cytidine deaminases as effectors in innate immunity against the hepatitis B virus.
Bonvin M; Greeve J
Curr Opin Infect Dis; 2008 Jun; 21(3):298-303. PubMed ID: 18448976
[TBL] [Abstract][Full Text] [Related]
78. Associations between activation-induced cytidine deaminase/apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like cytidine deaminase expression, hepatitis B virus (HBV) replication and HBV-associated liver disease (Review).
He X; Li J; Wu J; Zhang M; Gao P
Mol Med Rep; 2015 Nov; 12(5):6405-14. PubMed ID: 26398702
[TBL] [Abstract][Full Text] [Related]
79. MagnEdit-interacting factors that recruit DNA-editing enzymes to single base targets.
McCann JL; Salamango DJ; Law EK; Brown WL; Harris RS
Life Sci Alliance; 2020 Apr; 3(4):. PubMed ID: 32094150
[TBL] [Abstract][Full Text] [Related]
80. APOBEC3B is preferentially expressed at the G2/M phase of cell cycle.
Hirabayashi S; Shirakawa K; Horisawa Y; Matsumoto T; Matsui H; Yamazaki H; Sarca AD; Kazuma Y; Nomura R; Konishi Y; Takeuchi S; Stanford E; Kawaji H; Murakawa Y; Takaori-Kondo A
Biochem Biophys Res Commun; 2021 Mar; 546():178-184. PubMed ID: 33592502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
